0.23 USD
▲+0.01+2.56%
盘后 0.22 -0.36%
2026-08-03
市值
$10.48M
市盈率
—
EPS
-1.06
股息率
—
52 周区间
0.16 – 0.86
成交量
726.01K
Beta
1.09
目标价
2.50
52W 低 0.1652W 高 0.86
价格走势
公司简介
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma. The company also develops VCN-11 for treating solid tumors; SYN-004 (ribaxamase), an oral c...